v3.26.1
SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables)
 12 Months Ended
Mar. 28, 2026
Segment Reporting [Abstract]  
Segment Reporting
Selected information by reportable segment is presented below:
Year Ended
202620252024
(Dollars in Thousands)
Net revenues:
Plasma$524,456 $535,431 $569,535 
Blood Center221,267 261,124 283,231 
Hospital588,304 564,269 456,289 
Total net revenues$1,334,027 $1,360,824 $1,309,055 
Significant segment expenses and operating performance:
Plasma
Cost of goods sold$214,135 $237,050 $264,042 
Selling, general and administrative105,323 98,418 109,729 
Research and development20,203 15,453 13,797 
Plasma operating income$184,795 $184,510 $181,967 
Blood Center
Cost of goods sold$112,666 $142,512 $165,564 
Selling, general and administrative54,133 60,023 67,339 
Research and development4,492 5,770 7,956 
Blood Center operating income$49,976 $52,819 $42,372 
Hospital
Cost of goods sold$203,227 $199,499 $167,172 
Selling, general and administrative247,251 241,760 209,680 
Research and development34,091 34,035 27,239 
Hospital operating income$103,735 $88,975 $52,198 
Corporate and unallocated expenses
Amortization of acquired assets$(49,812)$(63,217)$(35,378)
Acquisition, integration and divestiture related costs(14,155)(22,904)(11,249)
Restructuring and restructuring related costs(3,218)(21,158)(23,588)
Digital transformation costs(21,526)(20,273)(15,667)
Remeasurement of contingent consideration1,879 23,022 — 
Impairment of intangible assets(86,546)(2,391)(10,419)
Other(1)
(8,394)2,434 (15,353)
Operating income156,734 221,817 164,883 
Interest and other expense, net(28,704)(9,746)(13,018)
Income before provision for income taxes$128,030 $212,071 $151,865 
__________
(1)    Comprised of write downs of certain assets, EU MDR and EU IVDR costs, Litigation-related charges, gain on repurchase of convertible notes, gain on sale of property, plant and equipment, PCS2® related charges, gain on divestiture, and a provision for pre-acquisition inventory and inventory purchase commitments transferred from the Attune Medical acquisition that was deemed not recoverable.
Net revenues by business unit are as follows:
Year Ended
202620252024
(Dollars in Thousands)
Plasma
Plasma net revenues$524,456 $535,431 $569,535 
Blood Center
Apheresis$220,861 $213,134 $211,173 
Whole Blood406 47,990 72,058 
Blood Center net revenues$221,267 $261,124 $283,231 
Hospital
Interventional Technologies$234,007 $255,019 $174,285 
Blood Management Technologies354,297 309,250 282,004 
Hospital net revenues$588,304 $564,269 $456,289 
Total net revenues$1,334,027 $1,360,824 $1,309,055 
Depreciation and amortization, excluding impairment charges, by business unit are as follows:
Year Ended
202620252024
(Dollars in Thousands)
Plasma$47,368 $48,264 $45,712 
Blood Center7,160 10,077 13,391 
Hospital57,189 57,245 38,112 
Total depreciation and amortization (excluding impairment charges)$111,717 $115,586 $97,215 
Long-lived assets, comprised of property, plant and equipment, by business unit are as follows:
March 28, 2026March 29, 2025
(Dollars in Thousands)
Plasma$206,365 $189,833 
Blood Center39,677 40,337 
Hospital59,719 53,882 
Total long-lived assets$305,761 $284,052 
Segment Information by Geographic Area
Long-lived assets, comprised of property, plant and equipment, by operating regions are as follows:
March 28, 2026March 29, 2025
(Dollars in Thousands)
United States$224,699 $217,212 
Japan916 1,250 
Europe32,080 20,024 
Rest of Asia30,833 28,705 
Other17,233 16,861 
Total long-lived assets$305,761 $284,052 
Net revenues by operating regions are as follows:
Year Ended
202620252024
(Dollars in Thousands)
United States$982,176 $1,010,918 $970,007 
Japan68,200 62,408 58,087 
Europe185,019 175,655 160,142 
Rest of Asia87,212 92,305 107,536 
Other11,420 19,538 13,283 
Total net revenues$1,334,027 $1,360,824 $1,309,055